Publications

Kayla L Nguyen, Ishaan J Bhatt, Shruti Gupta, Nazaf Showkat, Kathryn A Swanson, Roman Fischer, Roland E Kontermann, Klaus Pfizenmaier, Valerie Bracchi-Ricard, and John R Bethea. Tumor necrosis factor receptor 2 activation elicits sex-specific effects on cortical myelin proteins and functional recovery in a model of multiple sclerosis. Brain research bulletin, (207):110885--110885, United States, January 2024. [PUMA: izi 2024 pfizenmaier kontermann] URL

Natalia Ortí-Casañ, Ate S Boerema, Karina Köpke, Amber Ebskamp, Jan Keijser, Yuequ Zhang, Tingting Chen, Amalia M Dolga, Kerensa Broersen, Roman Fischer, Klaus Pfizenmaier, Roland E Kontermann, and Ulrich L M Eisel. The TNFR1 antagonist Atrosimab reduces neuronal loss, glial activation and memory deficits in an acute mouse model of neurodegeneration. Scientific reports, (13)1:10622--10622, England, June 2023. [PUMA: izi 2023 pfizenmaier kontermann] URL

E BECKER, L FLORIN, K PFIZENMAIER, and H KAUFMANN. An XBP-1 dependent bottle-neck in production of IgG subtype antibodies in chemically defined serum-free Chinese hamster ovary (CHO) fed-batch processes. Journal of Biotechnology, (135)2:217--223, Elsevier BV, June 2008. [PUMA: 2008 izi pfizenmaier] URL

Stephan A. Eisler, Yannick F. Fuchs, Klaus Pfizenmaier, and Angelika Hausser. G-PKDrep-live, a genetically encoded FRET reporter to measure PKD activity at the trans-Golgi-network. Biotechnology Journal, (7)1:148--154, January 2012. [PUMA: izi 2012 pfizenmaier hausser] URL

Sebastian Raeth, Benedetto Sacchetti, Georg Siegel, Ulrike a Mau-Holzmann, Jan Hansmann, Gabriele Vacun, Thomas G Hauk, Klaus Pfizenmaier, and Angelika Hausser. A mouse bone marrow stromal cell line with skeletal stem cell characteristics to study osteogenesis in vitro and in vivo.. Stem cells and development, (23)10:1097--108, May 2014. [PUMA: izi 2014 pfizenmaier hausser] URL

Jeannette Gerspach, Klaus Pfizenmaier, and Harald Wajant. Therapeutic Targeting of CD95 and the TRAIL Death Receptors. Recent Patents on Anti-Cancer Drug Discovery, (6)3:294--310, 2011. [PUMA: izi 2011 pfizenmaier] URL

Christian M. Joffroy, Miriam B. Buck, Matthias B. Stope, Simone L. Popp, Klaus Pfizenmaier, and Cornelius Knabbe. Antiestrogens induce transforming growth factor $\beta$-mediated immunosuppression in breast cancer. Cancer Research, (70)4:1314--1322, 2010. [PUMA: izi pfizenmaier 2010] URL

Roman Fischer, Roland E. Kontermann, and Klaus Pfizenmaier. Selective targeting of TNF receptors as a novel therapeutic approach. Frontiers in Cell and Developmental Biology, (8)Frontiers, 2020. [PUMA: izi fischer pfizenmaier 2020 kontermann] URL

Sylvia K.E. Messerschmidt, Anna Musyanovych, Martin Altvater, Peter Scheurich, Klaus Pfizenmaier, Katharina Landfester, and Roland E. Kontermann. Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells. Journal of Controlled Release, (137)1:69--77, 2009. [PUMA: 2009 izi pfizenmaier kontermann] URL

Kristin Wahl, Martin Siegemund, Frank Lehner, Florian Vondran, Andreas Nüssler, Florian Länger, Till Krech, Roland Kontermann, Michael P. Manns, Klaus Schulze-Osthoff, Klaus Pfizenmaier, and Heike Bantel. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology, (57)2:625--636, February 2013. [PUMA: izi 2013 pfizenmaier kontermann] URL

Martin Siegemund, Oliver Seifert, Maria Zarani, Tamara Dzinić, Valentino De Leo, Doris Göttsch, Sabine Münkel, Meike Hutt, Klaus Pfizenmaier, and Roland E. Kontermann. An optimized antibody-single-chain TRAIL fusion protein for cancer therapy. mAbs, (8)5:879--891, July 2016. [PUMA: 2016 izi pfizenmaier kontermann] URL

O. Seifert, A. Plappert, S. Fellermeier, M. Siegemund, K. Pfizenmaier, and R. E. Kontermann. Tetravalent Antibody-scTRAIL Fusion Proteins with Improved Properties. Molecular Cancer Therapeutics, (13)1:101--111, January 2014. [PUMA: izi 2014 pfizenmaier kontermann] URL

Mirita Franz-Wachtel, Stephan A. Eisler, Karsten Krug, Silke Wahl, Alejandro Carpy, Alfred Nordheim, Klaus Pfizenmaier, Angelika Hausser, and Boris Macek. Global Detection of Protein Kinase D-dependent Phosphorylation Events in Nocodazole-treated Human Cells. Molecular & Cellular Proteomics, (11)5:160--170, May 2012. [PUMA: izi 2012 pfizenmaier hausser] URL

Oliver Seifert, Nadine Pollak, Anja Nusser, Frank Steiniger, Ronny Rüger, Klaus Pfizenmaier, and Roland E. Kontermann. Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles. Bioconjugate Chemistry, (25)5:879--887, May 2014. [PUMA: izi 2014 pfizenmaier kontermann] URL

Myriam Fabre, Cristina Ferrer, Saioa Dominguez-Hormaetxe, Bruno Bockorny, Laura Murias, Oliver Seifert, Stephan A. Eisler, Roland E. Kontermann, Klaus Pfizenmaier, So Young Lee, Maria dM Vivanco, Pedro P Lopez-Casas, Sofia Perea, Muhammad Abbas, Wolfgang Richter, Laureano Simón, and Manuel Hidalgo. OMTX705, a Novel FAP-Targeting ADC demonstrates Activity in Chemotherapy and PD1-Resistant Solid Tumors Models. Clinical Cancer Research, clincanres.2238.2019, Clin Cancer Res, March 2020. [PUMA: izi pfizenmaier 2020 kontermann] URL

Yannick F. Fuchs, Stephan A. Eisler, Gisela Link, Oliver Schlicker, Gertrude Bunt, Klaus Pfizenmaier, and Angelika Hausser. A Golgi PKD activity reporter reveals a crucial role of PKD in nocodazole-induced Golgi dispersal. Traffic, (10)7:858--867, 2009. [PUMA: 2009 izi pfizenmaier hausser] URL

Julia Beisner, Miriam B. Buck, Peter Fritz, Jürgen Dippon, Matthias Schwab, Hiltrud Brauch, Gerhard Zugmaier, Klaus Pfizenmaier, and Cornelius Knabbe. A Novel Functional Polymorphism in the Transforming Growth Factor-β2 Gene Promoter and Tumor Progression in Breast Cancer. Cancer Research, (66)15:7554--7561, August 2006. [PUMA: 2006 izi pfizenmaier] URL

Roman Fischer, Marcel Proske, Maëlle Duffey, Hubert Stangl, George F. Martinez, Nathalie Peters, Alexandra Kraske, Rainer H. Straub, John R. Bethea, Roland E. Kontermann, and Klaus Pfizenmaier. Selective activation of tumor necrosis factor receptor 2 induces anti-inflammatory responses and alleviates experimental arthritis. Arthritis & Rheumatology, January 2018. [PUMA: 2018 izi pfizenmaier kontermann] URL

Katalin Czöndör, Kornelia Ellwanger, Yannick F Fuchs, Sylke Lutz, Márton Gulyás, Isabelle M Mansuy, Angelika Hausser, Klaus Pfizenmaier, and Katalin Schlett. Protein kinase D controls the integrity of Golgi apparatus and the maintenance of dendritic arborization in hippocampal neurons.. Molecular biology of the cell, (20)7:2108--20, 2009. [PUMA: 2009 izi pfizenmaier hausser] URL

D. Berg, M. Lehne, N. Müller, D. Siegmund, S. Münkel, W. Sebald, K. Pfizenmaier, and H. Wajant. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death and Differentiation, (14)12:2021--2034, 2007. [PUMA: 2007 izi pfizenmaier] URL